Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00402662
Status:
TERMINATED
Last Update Posted:
2013-12-18
First Post:
2006-11-20
Brief Title:
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
A Phase II Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
Status:
TERMINATED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
unexpected level of toxicity
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if the combination of everolimus and imatinib will slow the growth of or cause a reduction in the size of the cancer and to determine the side effects of the combination in patients with melanoma Each of the drugs in this combination if used alone would not be expected to have an effect against the cancer However when used together there is a possibility that they could work together to damage the cancer cells or to block the formation or function of the blood vessels that feed the cancer either of which could result in slowing the growth of or shrinking the cancer Both drugs work by blocking signals that are sent from outside of a cell to the inside of the cell that direct the cell to make certain substances to keep the cell alive Cancer cells or blood vessels that feed cancer cells may be more sensitive to drugs that block these signals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None